Amphastar Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid
Amphastar Pharmaceuticals, Inc. (AMPH) had Lessee, Operating Lease, Liability, to be Paid of $96.66 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2026-05-07
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid $96.66M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid $55.24M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid $59.31M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid $41.50M.
| Period end | Lessee, Operating Lease, Liability, to be Paid |
|---|---|
| 2026-03-31 | $96.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $55.24M 10-K · filed 2026-02-26 |
| 2024-12-31 | $59.31M 10-K · filed 2025-03-03 |
| 2023-12-31 | $41.50M 10-K · filed 2024-02-29 |
| 2022-12-31 | $32.43M 10-K · filed 2023-03-01 |
| 2021-12-31 | $34.37M 10-K · filed 2022-03-11 |
| 2020-12-31 | $26.23M 10-K · filed 2021-03-15 |
| 2019-12-31 | $24.97M 10-K · filed 2020-03-16 |
| 2019-09-30 | $25.80M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $26.54M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $15.87M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |